Cancer and Cardiovascular Disease: the Use of Novel Echocardiography Measures to Predict Subsequent Cardiotoxicity in Breast Cancer Treated with Anthracyclines and Trastuzumab

Gaurav Gulati, Kathleen W. Zhang, Marielle Scherrer-Crosbie, Bonnie Ky

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations

Abstract

As the population of breast cancer survivors grows, it has become evident that chemotherapy has significant cardiotoxic side effects. Echocardiography is a noninvasive, cost-effective, and widely available imaging tool that is well positioned to serve as a primary modality for monitoring chemotherapy-induced cardiotoxicity. Although left ventricular ejection fraction is a standard measurement by which to monitor chemotherapy-induced cardiotoxicity, its predictive value in identifying subsequent cardiotoxicity is limited. More sophisticated echocardiography modalities may offer improved sensitivity and specificity for detecting chemotherapy-induced cardiotoxicity. These include tissue Doppler imaging measures, newer techniques based upon two- and three-dimensional strain and torsion analysis, and three-dimensional measures of cardiac size. While these modalities are not all currently part of clinical practice, a body of data supporting their use is steadily building. More research remains to be performed, and noninvasively detecting cancer therapy-induced cardiac dysfunction at the earliest stages is of increasing interest.

Original languageEnglish (US)
Pages (from-to)366-373
Number of pages8
JournalCurrent heart failure reports
Volume11
Issue number4
DOIs
StatePublished - Dec 2014
Externally publishedYes

Keywords

  • Breast cancer
  • Cardiotoxicity
  • Chemotherapy
  • Echocardiography
  • Strain

ASJC Scopus subject areas

  • Emergency Medicine
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Fingerprint

Dive into the research topics of 'Cancer and Cardiovascular Disease: the Use of Novel Echocardiography Measures to Predict Subsequent Cardiotoxicity in Breast Cancer Treated with Anthracyclines and Trastuzumab'. Together they form a unique fingerprint.

Cite this